ALURD — Allurion Technologies Share News
0.000.00%
Last trade - 00:00- $7.48m
- $30.98m
- $15.23m
Brief: Allurion Announces Notification Of Issuance Of New U.S. Patents On Next-Generation Weight Loss Device For The Treatment Of Obesity
Allurion Tech dips on $6.1 million stock offering
Brief: Allurion To Raise Approximately $6.1 Million Of Gross Proceeds In Offering And Concurrent Private Placement To Advance Glp-1 Clinical Pipeline
Brief: Allurion Announces Plans To Combine Glp-1 Therapy With The Allurion Balloon To Treat Obesity
Brief: ANSM Clears Allurion To Resume Sales Of Allurion Balloon
Brief: Allurion Announces Private Placement Of Common Stock And Preliminary Unaudited Financial Results For The Fourth Quarter And Fiscal Year 2024
Brief: Allurion Reports Positive Topline Results From AUDACITY Trial
Brief: Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance
Brief: Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program
Allurion Technologies Inc reports results for the quarter ended September 30 - Earnings Summary
Allurion Technologies Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Allurion Announces Submission Of First Three Modules Of Premarket Approval Application To The U.S. Food And Drug Administration For The Allurion Balloon
Brief: Allurion Announces Publication Of New Data Demonstrating Weight Loss In Adolescents Suffering From Obesity
Brief: Allurion Appoints Adrian Wild As Senior Vice President
Brief: Allurion Gets NYSE Notice On Continued Listing Standards
Allurion Technologies Inc reports results for the quarter ended in June - Earnings Summary
Brief: Armistice Capital Reports 12.6% Passive Stake In Allurion Technologies
Allurion Technologies Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Allurion Technologies Says Agence Nationale De Sécurité Du Médicament, French Regulatory Authority, Has Suspended Sales Of Allurion Balloon In France